Table 9.
Scenario analysis results for mild-to-moderate AD patients compared with matched non-AD controls when considering the impact of the externally calculated productivity loss on the burden
| Output | THIN data | Projected data | ||||
|---|---|---|---|---|---|---|
| 2017 (n = 33,749)a | 2018 (n = 849,296)a | 2019 (n = 854,374)a | 2020 (n = 859,014)a | 2021 (n = 863,297)a | 2022 (n = 867,303)a | |
| AD patients | ||||||
| Drug | €316,020.14 | €7,952,667.93 | €8,000,222.18 | €8,043,669.95 | €8,083,769.93 | €8,121,288.35 |
| HCRU | €11,136,681.37 | €280,255,331.19 | €281,931,162.78 | €283,462,280.29 | €284,875,420.30 | €286,197,585.12 |
| Productivity loss costs | €53,473,905.18 | €1,305,562,571.49 | €1,313,369,391.75 | €1,320,502,065.06 | €1,327,085,143.04 | €1,333,244,415.35 |
| Matched non-AD controls | ||||||
| HCRU | €7,813,166.87 | €196,618,866.55 | €197,794,580.51 | €198,868,767.36 | €199,860,184.67 | €200,787,776.47 |
| Incremental costs (AD patients versus matched non-AD controls) | ||||||
| Incremental costs | €57,113,439.82 | €1,397,151,704.06 | €1,405,506,196.20 | €1,413,139,247.94 | €1,420,184,148.59 | €1,426,775,512.34 |
AD patients were propensity score matched with up to three non-AD controls based on demographics including age, sex, socio-economic status and practice ID
AD atopic dermatitis, HCRU healthcare resource utilisation, THIN The Health Improvement Network
aThe number of mild-to-moderate AD patients and matched non-AD controls;